Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind dose-exploration study of a 24-valent pneumococcal conjugate vaccine in participants aged 6 weeks and older
CTR20261940Phase 2Active
- Sponsor
- CanSino Biologics Inc.
- Start
- May 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Reinovax PCV24 in pneumococcal disease, sponsored by CanSino Biologics Inc.. Started May 2026; status: active.
02
Drugs
Reinovax PCV24
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20261940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261940.